Skip to main content
. 2009 Dec 30;35:44. doi: 10.1186/1824-7288-35-44

Figure 2.

Figure 2

Donor-derived alloreactive NK cells are able to kill leukaemia targets (this preventing disease recurrence), dendritic cells (DC) of the recipient (this preventing graft-versus-host disease recurrence) and cytotoxic T-lymphocytes of the recipient (this preventing graft rejection). Modified from Ruggeri et al. Science 2002.